Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-κB ligand signaling

Kim C. Mansky, Uma Sankar, Jiahuai Han, Michael C. Ostrowski

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

Receptor activator of NF-κB ligand (RANKL) activates signaling pathways that regulate osteoclast differentiation, function, and survival. The microphthalmia transcription factor (MITF) is required for terminal differentiation of osteoclasts. To determine whether MITF could be a target of RANKL signaling, a phosphospecific MITF antibody directed against conserved residue Ser307, a potential mitogen-activated protein kinase (MAPK) site, was produced. Using this antibody, we could demonstrate that MITF was rapidly and persistently phosphorylated upon stimulation of primary osteoclasts with RANKL and that phosphorylation of Ser307 correlated with expression of the target gene tartrate-resistant acid phosphatase. MITF phosphorylation at Ser307 also correlated with persistent activation of p38 MAPK, and p38 MAPK could utilize MITF Ser307 as a substrate in vitro. The phosphorylation of MITF and activation of target gene expression in osteoclasts were blocked by p38 MAPK inhibitor SB203580. In transient transfections, a constitutively active Rac1 or MKK6 gene could collaborate with MITF to activate the tartrate-resistant acid phosphatase gene promoter dependent on Ser307. Dominant negative p38 α and β could inhibit the collaboration between upstream signaling components and MITF in the transient assays. These results indicate that MITF is a target for the RANKL signaling pathway in osteoclasts and that phosphorylation of MITF leads to an increase in osteoclast-specific gene expression.

Original languageEnglish (US)
Pages (from-to)11077-11083
Number of pages7
JournalJournal of Biological Chemistry
Volume277
Issue number13
DOIs
StatePublished - Mar 29 2002
Externally publishedYes

Fingerprint

Microphthalmia-Associated Transcription Factor
p38 Mitogen-Activated Protein Kinases
Ligands
Osteoclasts
Phosphorylation
Genes
Gene Expression
Acid Phosphatase
Gene expression
Chemical activation
Microphthalmos
Antibodies
Protein Kinase Inhibitors
Mitogen-Activated Protein Kinases
Transcriptional Activation
Transfection
Assays

ASJC Scopus subject areas

  • Biochemistry

Cite this

Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-κB ligand signaling. / Mansky, Kim C.; Sankar, Uma; Han, Jiahuai; Ostrowski, Michael C.

In: Journal of Biological Chemistry, Vol. 277, No. 13, 29.03.2002, p. 11077-11083.

Research output: Contribution to journalArticle

@article{6ed6c04d6c294e6981feff18bce2de72,
title = "Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-κB ligand signaling",
abstract = "Receptor activator of NF-κB ligand (RANKL) activates signaling pathways that regulate osteoclast differentiation, function, and survival. The microphthalmia transcription factor (MITF) is required for terminal differentiation of osteoclasts. To determine whether MITF could be a target of RANKL signaling, a phosphospecific MITF antibody directed against conserved residue Ser307, a potential mitogen-activated protein kinase (MAPK) site, was produced. Using this antibody, we could demonstrate that MITF was rapidly and persistently phosphorylated upon stimulation of primary osteoclasts with RANKL and that phosphorylation of Ser307 correlated with expression of the target gene tartrate-resistant acid phosphatase. MITF phosphorylation at Ser307 also correlated with persistent activation of p38 MAPK, and p38 MAPK could utilize MITF Ser307 as a substrate in vitro. The phosphorylation of MITF and activation of target gene expression in osteoclasts were blocked by p38 MAPK inhibitor SB203580. In transient transfections, a constitutively active Rac1 or MKK6 gene could collaborate with MITF to activate the tartrate-resistant acid phosphatase gene promoter dependent on Ser307. Dominant negative p38 α and β could inhibit the collaboration between upstream signaling components and MITF in the transient assays. These results indicate that MITF is a target for the RANKL signaling pathway in osteoclasts and that phosphorylation of MITF leads to an increase in osteoclast-specific gene expression.",
author = "Mansky, {Kim C.} and Uma Sankar and Jiahuai Han and Ostrowski, {Michael C.}",
year = "2002",
month = "3",
day = "29",
doi = "10.1074/jbc.M111696200",
language = "English (US)",
volume = "277",
pages = "11077--11083",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "13",

}

TY - JOUR

T1 - Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-κB ligand signaling

AU - Mansky, Kim C.

AU - Sankar, Uma

AU - Han, Jiahuai

AU - Ostrowski, Michael C.

PY - 2002/3/29

Y1 - 2002/3/29

N2 - Receptor activator of NF-κB ligand (RANKL) activates signaling pathways that regulate osteoclast differentiation, function, and survival. The microphthalmia transcription factor (MITF) is required for terminal differentiation of osteoclasts. To determine whether MITF could be a target of RANKL signaling, a phosphospecific MITF antibody directed against conserved residue Ser307, a potential mitogen-activated protein kinase (MAPK) site, was produced. Using this antibody, we could demonstrate that MITF was rapidly and persistently phosphorylated upon stimulation of primary osteoclasts with RANKL and that phosphorylation of Ser307 correlated with expression of the target gene tartrate-resistant acid phosphatase. MITF phosphorylation at Ser307 also correlated with persistent activation of p38 MAPK, and p38 MAPK could utilize MITF Ser307 as a substrate in vitro. The phosphorylation of MITF and activation of target gene expression in osteoclasts were blocked by p38 MAPK inhibitor SB203580. In transient transfections, a constitutively active Rac1 or MKK6 gene could collaborate with MITF to activate the tartrate-resistant acid phosphatase gene promoter dependent on Ser307. Dominant negative p38 α and β could inhibit the collaboration between upstream signaling components and MITF in the transient assays. These results indicate that MITF is a target for the RANKL signaling pathway in osteoclasts and that phosphorylation of MITF leads to an increase in osteoclast-specific gene expression.

AB - Receptor activator of NF-κB ligand (RANKL) activates signaling pathways that regulate osteoclast differentiation, function, and survival. The microphthalmia transcription factor (MITF) is required for terminal differentiation of osteoclasts. To determine whether MITF could be a target of RANKL signaling, a phosphospecific MITF antibody directed against conserved residue Ser307, a potential mitogen-activated protein kinase (MAPK) site, was produced. Using this antibody, we could demonstrate that MITF was rapidly and persistently phosphorylated upon stimulation of primary osteoclasts with RANKL and that phosphorylation of Ser307 correlated with expression of the target gene tartrate-resistant acid phosphatase. MITF phosphorylation at Ser307 also correlated with persistent activation of p38 MAPK, and p38 MAPK could utilize MITF Ser307 as a substrate in vitro. The phosphorylation of MITF and activation of target gene expression in osteoclasts were blocked by p38 MAPK inhibitor SB203580. In transient transfections, a constitutively active Rac1 or MKK6 gene could collaborate with MITF to activate the tartrate-resistant acid phosphatase gene promoter dependent on Ser307. Dominant negative p38 α and β could inhibit the collaboration between upstream signaling components and MITF in the transient assays. These results indicate that MITF is a target for the RANKL signaling pathway in osteoclasts and that phosphorylation of MITF leads to an increase in osteoclast-specific gene expression.

UR - http://www.scopus.com/inward/record.url?scp=0037192784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037192784&partnerID=8YFLogxK

U2 - 10.1074/jbc.M111696200

DO - 10.1074/jbc.M111696200

M3 - Article

C2 - 11792706

AN - SCOPUS:0037192784

VL - 277

SP - 11077

EP - 11083

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 13

ER -